Tracker

CDSCO approvals

CDSCO's list of new drug and clinical trial approvals holds 322 permission letters dated 2023, from January 3, 2023 to December 29, 2023. GCT is the most common kind of permission, with 145. Each row gives the company, product, kind of permission, date and a link to the letter, and CDSCO's file number where its text gives it.

From CDSCO's CT Approvals list, read . Each product links to CDSCO's PDF of its letter. The date is the one CDSCO gives on its list; the file number is printed in the letter. Not stated: file number on 3 rows. The file number is not read from 124 scanned letters: we read a letter's text, not its image. CDSCO's link did not open for 5 letters, so its file number is not shown.

The kinds of permission are CDSCO's own. FDC is fixed-dose combination (CDSCO's guidance for its Subject Expert Committees, page 13); GCT is global clinical trial (CDSCO's FAQs on the New Drugs and Clinical Trials Rules, page 8); IND is Investigational New Drug (CDSCO's guidance for its Subject Expert Committees, page 3); SND is Subsequent New Drugs (CDSCO's Citizen's Charter, page 2); rDNA is recombinant Deoxyribonucleic Acid (CDSCO's FAQs on the New Drugs and Clinical Trials Rules, page 3, which that page writes r-DNA).

December 2023

November 2023

October 2023

September 2023

August 2023

July 2023

June 2023

May 2023

April 2023

March 2023

February 2023

January 2023